Objective: To observe the effect of Xuezhikang capsule on the inflammatory factors

endothelial function and carotid atherosclerotic plaques(CAP)in patients with unstable angina pectoris(UAP). Method: Eighty-two cases of UAP and CAP patients were randomly divided into two groups:the control group received conventional therapy+rosuvastatin

Xuezhikang group received Xuezhikang capsule

2 capsules once

three times daily

based on the control group.Both groups were given continuous medication for 12 months. Lipids

inflammation

endothelial function indicators and CAP were detected before and after treatment

clinical efficacy in patients of two groups were observed after 12 months of treatment

cardiovascular events were followed up for 12 months. Result: After 12 months of treatment

the total efficiency of Xuezhikang group was significantly higher than that of the control group (P<0.05);there were significant differences between the two groups and the health group in blood lipids

inflammation

endothelial function and intima-media thickness(IMT) values and the area of the CAP(all P<0.01);the improvement of blood lipids

inflammation

endothelial function and IMT values and the area of the CAP in Xuezhikang group was significantly better than that of the control group(all P<0.01); the incidence of cardiovascular events of Xuezhikang group was significantly lower than that of the control group(P<0.05);there was no significant difference between two groups in the incidence of adverse drug reactions. Conclusion: Xuezhikang reduce cardiovascular events by improve endothelial function

reducing the inflammatory response

reversal and stable carotid atherosclerotic plaque

and no increase in adverse effects.